Thermo Fisher Scientific Launches CE-IVD (IVDD) Next-Generation Sequencing Test and Analysis Software to Expand Access to Precision Oncology Biomarker Testing
Next-generation sequencing (NGS) is quickly becoming the platform of choice for tumor molecular profiling due to its ability to simultaneously report on multiple biomarkers. However, lengthy turnaround times can limit the clinical utility of these results. To meet the need for rapid genomic insights, Thermo Fisher Scientific today launched the CE-IVD (IVDD) Oncomine Dx Express Test and Oncomine Reporter Dx for use in clinical labs.
Using targeted NGS technology, the Oncomine Dx Express Test delivers clinically relevant tumor mutation profiling in as little as 24 hours to aid healthcare professionals, in accordance with professional guidelines, in therapy management of cancer patients. The qualitative in vitro diagnostic (IVD) test detects deletions, insertions, substitutions and copy number gain present in 42 genes and fusions or splicing variants in 18 genes from DNA and RNA in FFPE tumor tissue samples of solid malignant neoplasms. This assay also detects deletions, insertions, substitutions in 42 genes and fusions or splicing variants in seven genes from cfTNA extracted from plasma samples of non-small cell lung cancer (NSCLC). The assay requires minimal sample input, maximizing sample success rates.
The Oncomine Reporter Dx software ensures healthcare providers can quickly assess the genomic test results. The software matches the variant data to relevant evidence including approved therapies, guidelines, clinical trials and peer reviewed literature in a user-friendly and customizable report.
“Genomic profiling in precision oncology is transforming cancer care, but true clinical utility hinges on timely, actionable results,” said Garret Hampton, president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific. “By delivering an IVD NGS solution that provides rapid results with minimal training and hands-on time, we’re working to make these insights available in any lab or hospital to help connect patients to precision oncology treatments.”
The new NGS assay and genomic reporting software, along with the recently launched Ion Torrent Genexus Dx Integrated Sequencer, offer an automated end-to-end CE-IVD workflow. Operated from a single software interface, the overall process includes less than 20 minutes of hands-on time, delivering results with unprecedented rapid turnaround time. The workflow enables any lab to bring the power of genomic testing in-house, improves access to patients and advances precision oncology for those who stand to benefit most.
For more information on the Oncomine Dx Express Test and the Oncomine Reporter Dx, please visit oncomine.com/express-test.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Neustar Security Services expands partner network in EMEA27.9.2022 15:00:00 EEST | Press release
Neustar Security Services, a leading provider of cloud-oriented security services that enable global businesses to thrive online, has expanded its partner ecosystem across key technology hubs in the Europe, Middle East and Africa region. The company’s new partners include CyberArm in Lebanon; Infinity IT in the Netherlands; Arcane BT in Turkey; Caretower, an Integrity 360 Company, in the U.K.; and K-Tel in Germany. The partner expansion is the latest in a series of milestones as Neustar Security Services evolves its business and industry-leading solutions across the EMEA region. The signing of CyberArm, the company’s first partner in the Middle East, coincides with the opening of a new data scrubbing center in Dubai, its 15th global node. The company continues to invest in increasing the capacity and resilience of its network, which now boasts more than 15 Terabits per second (Tbps) of total distributed-denial-of-service (DDoS) attack mitigation scrubbing capacity globally. “Partners a
Aktana and Envision Pharma Group Partner to Help Medical Affairs Navigate the Evolving Physician Engagement Landscape27.9.2022 14:33:00 EEST | Press release
Aktana, the leader in intelligent customer engagement for the life sciences industry, and Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs, announce a strategic partnership that provides medical teams with a comprehensive toolkit for more impactful scientific exchange. By bringing together their extensive technical and industry expertise, Envision and Aktana offer life science companies the ability to enable their medical science liaisons (MSLs) to address HCP demands for personalized, scientifically relevant content and coordinated omnichannel engagement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005291/en/ Despite the industry’s separation between commercial and medical teams, today’s HCPs expect MSLs to operate with a holistic view of their engagement with the product. While many life sciences companies have already started equi
FourKites Announces $10M Strategic Investment from Mitsui & Co. to Transform Supply Chains in Asia-Pacific27.9.2022 14:30:00 EEST | Press release
Leading supply chain visibility company FourKites today announces a $10M investment from Mitsui & Co., Ltd. to expand FourKites’ offerings across the APAC region. This investment encompasses the first phase in an ongoing strategic relationship between FourKites and Mitsui, which the two companies intend to formalise by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005141/en/ FourKites Announces $10M Strategic Investment from Mitsui & Co. to Transform Supply Chains in Asia-Pacific (Graphic: Business Wire) Mitsui’s investment in FourKites is the culmination of a yearlong effort between the two companies, which included Mitsui’s extensive due diligence of the supply chain visibility landscape. Given FourKites’ market-leading offerings and proven track record in the region, Mitsui is planning to invest significant resources to expand FourKites’ coverage in APAC, including sales, customer service, oper
Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients27.9.2022 14:00:00 EEST | Press release
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the new availability of plasmid DNA manufacturing to its suite of scalable manufacturing services for gene therapy programs, complementing Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities. Forge’s plasmid manufacturing services encompass three grades to accommodate a phase-appropriate approach: Research-Grade, suitable for discovery, research and development; GMP-Pathway, suitable for early-stage clinical trial cGMP AAV manufacturing, and cGMP, suitable for late-stage clinical and commercial cGMP manufacturing. Forge’s plasmid production services utilize single-use systems that seamlessly integrate into the Company’s platform AAV manufacturing process, allowing continuity of manufacturing for clients and streamlined vendor management. Research-Grade and GMP-Pathway plasmid grades are currently available,
DOQMIND Announces Peter Hulsmans as CEO27.9.2022 14:00:00 EEST | Press release
DOQMIND (www.DOQMIND.com), a leading label and artwork management technology provider, announced today that Peter Hulsmans has been appointed CEO. With more than 20 years of label and artwork management leadership experience, Hulsmans brings a high-growth, customer-focused mindset to DOQMIND. “Peter’s experience and extensive industry knowledge make him the right person to build momentum and drive DOQMIND’s aggressive expansion plans,” said Ignace Cosaert, a board member of Athena Graphics, DOQMIND’s founding company. “Peter is known in the industry as someone who always delivers on his customer commitments, aligned with Athena’s reputation for delivering high-quality prepress services since 1991. He will be an excellent steward of our values, products, and brand portfolio.” DOQMIND has been providing label and artwork management technology to some of the most well-known brands for the last 15 years as part of Athena’s product portfolio. Its growth has positioned the company to spin of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom